The estimated Net Worth of Harvey Lalach is at least $2.94 Milhão dollars as of 24 May 2012. Harvey Lalach owns over 18,572 units of Anavex Life Sciences stock worth over $2,821,500 and over the last 16 years Harvey sold AVXL stock worth over $114,838.
Harvey has made over 5 trades of the Anavex Life Sciences stock since 2011, according to the Form 4 filled with the SEC. Most recently Harvey sold 18,572 units of AVXL stock worth $17,086 on 24 May 2012.
The largest trade Harvey's ever made was selling 18,572 units of Anavex Life Sciences stock on 24 May 2012 worth over $17,086. On average, Harvey trades about 6,250 units every 58 days since 2008. As of 24 May 2012 Harvey still owns at least 550,000 units of Anavex Life Sciences stock.
You can see the complete history of Harvey Lalach stock trades at the bottom of the page.
Harvey's mailing address filed with the SEC is 4837 CANYON RIDGE CRESENT, , KELOWNA, A1, V1W 4A1.
Over the last 18 years, insiders at Anavex Life Sciences have traded over $5,238,591 worth of Anavex Life Sciences stock and bought 135,460 units worth $453,776 . The most active insiders traders include Athanasios Skarpelos, Christopher U Missling, eElliot Favus. On average, Anavex Life Sciences executives and independent directors trade stock every 99 days with the average trade being worth of $335,876. The most recent stock trade was executed by Peter D.O. Donhauser on 14 June 2024, trading 2,835 units of AVXL stock currently worth $10,319.
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
Anavex Life Sciences executives and other stock owners filed with the SEC include: